ArticleScientific reports2025
Exploration of autophagy-associated genes and potential molecular mechanisms in type 1 diabetes and osteoporosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Semaglutide attenuates diabetic vascular calcification by enhancing autophagy and lysosomal function via targeting CPNE1.Apoptosis : an international journal on programmed cell death · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The co-occurrence of osteoporosis (OP) and type 1 diabetes mellitus (T1DM) represents a clinically significant comorbidity pattern, characterized by skeletal fragility and insulin deficiency. While epidemiological links exist, their shared molecular mechanisms remain undefined. This study investigates autophagy-a critical cellular degradation pathway-as a potential mechanistic bridge between OP and T1DM pathogenesis. We integrated multi-omics approaches using GEO datasets to identify autophagy- associated hub genes. Machine learning (LASSO/Random Forest) prioritized CPNE1 and FRAT2, validated through ROC curve analysis. Functional annotation via GO/KEGG enrichment analyses revealed enrichment in disease-associated pathways, corroborated by immune infiltration profiling and single-cell RNA sequencing showing cell-type-specific expression patterns. miRNA-gene regulatory networks further elucidated post-transcriptional control mechanisms. Our integrated analyses suggest that CPNE1 and FRAT2 may represent novel targets for combined diagnosis and therapy in OP and T1DM, where autophagic dysregulation could contribute to comorbid pathogenesis. These insights offer fresh perspectives for developing dual-disease management approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.